Endpoints
tumor, peritoneal lesions
DISEASE, TUMOR, PERITONEAL LESION, SECONDARY
The primary endpoint for the current trial will be the peritoneal response rate after four cycles of IPC associated with systemic CMT. The evaluation will be performed during a second SL as follows:Complete peritoneal response: the disappearance of all peritoneal lesions, with negative biopsy for tumor cells in the intraoperative frozen section and/or cytology negativePartial response: reduction of peritoneal lesions, but with positive cytology and/or positive biopsy for tumor cells in the intraoperative frozen sectionNo response: stable disease in the peritoneumDisease progression: increase in lesions in the peritoneumAs secondary endpoints, the clinical trial will assess the following parameters:




